ct327
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT01243502)
Timeline
Indications
Mechanism of action
- Nerve growth factor receptor Trk-AINHIBITOR
NTRK1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545152 ↗
Also known as
- ct327
- ct 327
- ct 327
- ct-327
- ct-327
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01808157 | Phase 2 | Jul 1, 2013 | Creabilis SA |
| NCT01465282 | Phase 2 | Dec 1, 2011 | Creabilis SA |
| NCT01368315 | Phase 1 | Jun 6, 2011 | Creabilis SA |
| NCT01243307 | Phase 1 | Jan 1, 2011 | Aalborg University, Creabilis SA |
| NCT00995969 | Phase 2 | Mar 1, 2010 | Creabilis SA |
| NCT00996008 | Phase 2 | Nov 1, 2009 | Creabilis SA |
| NCT01243502 | Phase 1 | Sep 1, 2007 | Creabilis SA, LCG Bioscience |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Creabilis SA | For profit | 7 | 7 | 2 | 2007 |
| Aalborg University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| LCG Bioscience | For profit | 1 | 0 | 1 | 2007 |
3 organizations
Page 1 / 1